Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Am Heart Assoc
2020 May 18;910:e015751. doi: 10.1161/JAHA.119.015751.
Show Gene links
Show Anatomy links
Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
Wiedmann F
,
Beyersdorf C
,
Zhou X
,
Büscher A
,
Kraft M
,
Nietfeld J
,
Walz TP
,
Unger LA
,
Loewe A
,
Schmack B
,
Ruhparwar A
,
Karck M
,
Thomas D
,
Borggrefe M
,
Seemann G
,
Katus HA
,
Schmidt C
.
???displayArticle.abstract???
Background The tandem of P domains in a weak inward rectifying K+ channel (TWIK)-related acid-sensitive K+ channel (TASK-1; hK2P3.1) two-pore-domain potassium channel was recently shown to regulate the atrial action potential duration. In the human heart, TASK-1 channels are specifically expressed in the atria. Furthermore, upregulation of atrial TASK-1 currents was described in patients suffering from atrial fibrillation (AF). We therefore hypothesized that TASK-1 channels represent an ideal target for antiarrhythmic therapy of AF. In the present study, we tested the antiarrhythmic effects of the high-affinity TASK-1 inhibitor A293 on cardioversion in a porcine model of paroxysmal AF. Methods and Results Heterologously expressed human and porcine TASK-1 channels are blocked by A293 to a similar extent. Patch clamp measurements from isolated human and porcine atrial cardiomyocytes showed comparable TASK-1 currents. Computational modeling was used to investigate the conditions under which A293 would be antiarrhythmic. German landrace pigs underwent electrophysiological studies under general anesthesia. Paroxysmal AF was induced by right atrial burst stimulation. After induction of AF episodes, intravenous administration of A293 restored sinus rhythm within cardioversion times of 177±63 seconds. Intravenous administration of A293 resulted in significant prolongation of the atrial effective refractory period, measured at cycle lengths of 300, 400 and 500 ms, whereas the surface ECG parameters and the ventricular effective refractory period lengths remained unchanged. Conclusions Pharmacological inhibition of atrial TASK-1 currents exerts antiarrhythmic effects in vivo as well as in silico, resulting in acute cardioversion of paroxysmal AF. Taken together, these experiments indicate the therapeutic potential of A293 for AF treatment.
Antigny,
Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.
2016, Pubmed
Antigny,
Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension.
2016,
Pubmed
Arnold,
The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.
2006,
Pubmed
Bayliss,
Emerging roles for two-pore-domain potassium channels and their potential therapeutic impact.
2008,
Pubmed
Biasini,
SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information.
2014,
Pubmed
Courtemanche,
Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model.
1998,
Pubmed
Fabritz,
Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment.
2016,
Pubmed
Goldstein,
Potassium leak channels and the KCNK family of two-P-domain subunits.
2001,
Pubmed
Guex,
Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective.
2009,
Pubmed
January,
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
2019,
Pubmed
Kiefer,
The SWISS-MODEL Repository and associated resources.
2009,
Pubmed
Kim,
Role of K₂p channels in stimulus-secretion coupling.
2015,
Pubmed
Kiper,
Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?
2015,
Pubmed
,
Xenbase
Kirchhof,
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
2016,
Pubmed
Kitagawa,
Hemodynamic and Pathologic Characterization of the TASK-1-/- Mouse Does Not Demonstrate Pulmonary Hypertension.
2017,
Pubmed
Limberg,
TASK-1 channels may modulate action potential duration of human atrial cardiomyocytes.
2011,
Pubmed
,
Xenbase
Lloyd,
Disruption of K(2P)6.1 produces vascular dysfunction and hypertension in mice.
2011,
Pubmed
Lolicato,
K2P2.1 (TREK-1)-activator complexes reveal a cryptic selectivity filter binding site.
2017,
Pubmed
,
Xenbase
Ma,
A novel channelopathy in pulmonary arterial hypertension.
2013,
Pubmed
Matene,
Fully automated initiation of simulated episodes of atrial arrhythmias.
2012,
Pubmed
Morris,
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.
2009,
Pubmed
Murtaza,
TASK-1 potassium channel is not critically involved in mediating hypoxic pulmonary vasoconstriction of murine intra-pulmonary arteries.
2017,
Pubmed
Olschewski,
Impact of TASK-1 in human pulmonary artery smooth muscle cells.
2006,
Pubmed
Olschewski,
Letter by Olschewski et al Regarding Article, "Upregulation of K2P3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation".
2016,
Pubmed
Patel,
Molecular physiology of oxygen-sensitive potassium channels.
2001,
Pubmed
Putzke,
The acid-sensitive potassium channel TASK-1 in rat cardiac muscle.
2007,
Pubmed
,
Xenbase
Putzke,
Differential effects of volatile and intravenous anesthetics on the activity of human TASK-1.
2007,
Pubmed
,
Xenbase
Ravens,
Novel pharmacological approaches for antiarrhythmic therapy.
2010,
Pubmed
Rinné,
TASK-1 and TASK-3 may form heterodimers in human atrial cardiomyocytes.
2015,
Pubmed
,
Xenbase
Schmidt,
Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy.
2017,
Pubmed
Schmidt,
Upregulation of K(2P)3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation.
2015,
Pubmed
Schmidt,
Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure.
2014,
Pubmed
,
Xenbase
Schmidt,
Genetic Ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K+ Channel-Related Acid-Sensitive K+ Channel-1) (K2P3.1) K+ Channels Suppresses Atrial Fibrillation and Prevents Electrical Remodeling.
2019,
Pubmed
Schmidt,
Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels.
2013,
Pubmed
,
Xenbase
Trott,
AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.
2010,
Pubmed
Vigmond,
Solvers for the cardiac bidomain equations.
2008,
Pubmed
Wiedmann,
Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
2021,
Pubmed
,
Xenbase
Wiedmann,
Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K2P) channels in murine disease models: focus on TASK-1.
2018,
Pubmed
,
Xenbase
Wiedmann,
N-glycosylation-dependent regulation of hK2P17.1 currents.
2019,
Pubmed
,
Xenbase
Wiedmann,
Identification of the A293 (AVE1231) Binding Site in the Cardiac Two-Pore-Domain Potassium Channel TASK-1: a Common Low Affinity Antiarrhythmic Drug Binding Site.
2019,
Pubmed
,
Xenbase
Wiedmann,
Therapeutic targeting of two-pore-domain potassium (K(2P)) channels in the cardiovascular system.
2016,
Pubmed
Wilhelms,
Benchmarking electrophysiological models of human atrial myocytes.
2012,
Pubmed
Wirth,
In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231.
2007,
Pubmed
